| Aug 8 |
Aldeyra climbs after late-stage success for dry eye disease therapy
|
| Aug 8 |
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
|
| Aug 7 |
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
|
| Jul 31 |
Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
|
| Jun 20 |
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
|
| Jun 14 |
Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial
|
| Jun 13 |
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
|
| Jun 12 |
Aldeyra Therapeutics to Host Investor Roundtable Q&A
|
| Jun 10 |
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
|
| May 29 |
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
